Register
Forgot your password?

Prosthetics of the pulmonary artery valve in children with congenital heart defects: the experience of one center

Authors: Lyapin A.A., Tarasov R.S., Ivkin A.A

Company: Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation

For correspondence:  Sign in or register.

Type:  Original articles


DOI: https://doi.org/10.24022/1997-3187-2026-20-1- 137-146

For citation: Lyapin A.A., Tarasov R.S., Ivkin A.A. Prosthetics of the pulmonary artery valve in children with congenital heart defects: the experience of one center. Creative Cardiology. 2026; 20 (1): 137–146 (in Russ.). DOI: 10.24022/1997-3187-2026-20-1-137-146

Received / Accepted:  23.01.2026 / 05.03.2026

Keywords: congenital heart defect pulmonary valve regurgitation pulmonary valve replacement



Subscribe 🔒

 

Abstract

Objective. To evaluate the outcomes of pulmonary valve replacement in the pediatric group during the hospital and remote postoperative periods.

Material and methods. The retrospective study included 25 children (15 boys and 10 girls; median age 139.92±53.39 months) with chronic pulmonary valve insufficiency following prior surgical intervention for congenital heart disease involving the pulmonary valve.

Results. Twenty-five conduits were implanted (5 Contegra, 7 Shelhigh/Pylon, 13 allograft). Mean cardiopulmonary bypass time was 77 minutes, and mean aortic cross-clamp time was 42 minutes. Acute cerebral blood flow disturbance occurred in one child (4%). The maximum pressure gradient across the conduit at discharge was 15 mm Hg. No in-hospital mortality was observed. The length of stay in the intensive care unit was 2 days, and the total hospital stay was 12 days.

Conclusion. Pulmonary valve replacement is the “gold standard” for treating chronic pulmonary regurgitation in children with congenital heart disease, associated with low in-hospital mortality and perioperative complications, reducing heart failure severity. No significant differences in outcomes were found among the three conduit types over a six-month follow- up.

References

  1. Jwan A.N., Hossam I., Kartik A. et al. Prevalence, a etiology, and outcomes of native pulmonary regurgitation in the general adult population. Eur. Heart J. Cardiovasc. Imaging. 2025; 26 (4): 695–702. DOI: 10.1093/ehjci/jeaf011
  2. Shimazaki Y., Blackstone E.H., Kirklin J.W. The natural history of isolated congenital pulmonary valve incompetence: surgical implications. Thorac. Cardiovasc. Surg. 1984; 32: 257–259. DOI: 10.1055/s-2007-1023399
  3. Geva T. Indications and timing of pulmonary valve replacement after tetralogy of Fallot repair. Semin. Thorac. Cardiovasc. Surg. Pediatr. Card. Surg. Annu. 2006; 11–22. DOI: 10.1053/j.pcsu.2006.02.009
  4. Dobbels B., Herregods M.C., Troost E. et al. Early versus late pulmonary valve replacement in patients with transannular patch-repaired tetralogy of Fallot. Interact. Cardiovasc. Thorac. Surg. 2017; 25: 427–433. DOI: 10.1093/icvts/ivx118
  5. Baumgartner H., De Backer J., Babu-Narayan S.V. et al. ESC Scientific Document Group. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur. Heart J. 2021; 42 (6): 563–645. DOI: 10.1093/eurheartj/ehaa554
  6. Karas’kov A., Demin I., Sharifulin R. et al. Different types of conduits for right ventricular outflow tract reconstruction during the ross procedure in adults: a comparative analysis. Circ. Patho. Card. Surg. 2013; 223–227 (in Russ.). DOI: 10.21688/1681-3472-2013-2-23-27
  7. Ivkin A.A., Borisenko D.V., Tsepokina A.V. et al. Renouncement of red blood cells for heart-lung machine filling for perioperative prevention of cerebral injury in children undergoing cardiac surgery. Russian Journal of Anesthesiology and Reanimatology. 2021; 4: 56–63 (in Russ.). DOI: 10.17116/anaesthesiology202104156
  8. Lyapin A.A. Key technical aspects and results of radical correction of the tetralogy of Fallot in children after right ventricular outflow tract stenting: emphasis on the pulmonary artery valve. Complex Issues of Cardiovascular Diseases. 2024; 13 (3S): 66–73 (in Russ.). DOI: 10.17802/2306-1278-2024-13-3S-66-73
  9. Yamamura K., Yuen D., Hickey E.J. et al. Right ventricular fibrosis is associated with cardiac remodelling after pulmonary valve replacement. Heart. 2019; 105 (11): 855–863. DOI: 10.1136/heartjnl-2018-313961
  10. Lyapin A.A., Tarasov R.S. Transannular repair in the radical correction of tetralogy of Fallot – what next? Creative Cardiology. 2025; 19 (2): 146–154 (in Russ.). DOI: 10.24022/1997-3187-2025-19-2-146-154
  11. Mongeon F.P., Ben Ali W., Khairy P. et al. Pulmonary valve replacement for pulmonary regurgitation in adults with tetralogy of fallot: a meta-analysis-a report for the writing Committee of the 2019 Update of the Canadian Cardiovascular Society Guidelines for the management of adults with congenital heart disease. Can. J. Cardiol. 2019; 35 (12): 1772–1783. DOI: 10.1016/j.cjca.2019.08.031
  12. Ferraz Cavalcanti P.E., Sá M.P., Santos C.A. et al. Pulmonary valve replacement after operative repair of tetralogy of Fallot: meta-analysis and meta-regression of 3,118 patients from 48 studies. J. Am. Coll. Cardiol. 2013; 62 (23): 2227–2243. DOI: 10.1016/j.jacc.2013.04.107
  13. Ait-Ali L., Leonardi B., Alaimo A. et al. CMR/CT WG of Italian Pediatric Cardiology Society. Overcoming underpowering in the outcome analysis of repaired – tetralogy of Fallot: a multicenter database from the CMR/CT working group of the Italian Pediatric Cardiology Society (SICPed). Diagnostics (Basel). 2023; 13 (20): 3255. DOI: 10.3390/diagnostics13203255
  14. Troshkinev N.M., Tarasov R.S. Transcatheter pulmonary valve replacement for congenital heart defects. Russian Journal of Cardiology and Cardiovascular Surgery. 2023; 6 (2): 161–170 (in Russ.). DOI: 10.17116/kardio202316021161
  15. Valente A.M., Gauvreau K., Assenza G.E. et al. Rationale and design of an international multicenter registry of patients with repaired tetralogy of Fallot to define risk factors for late adverse outcomes: the INDICATOR cohort. Pediatr. Cardiol. 2013; 34 (1): 95–104. DOI: 10.1007/s00246-012-0394-5
  16. Kulyabin Yu.Yu., Nichay N.R., Soynov I.A. et al. Comparative analysis of pulmonary artery conduits in children. Complex Issues of Cardiovascular Diseases. 2024; 13 (4): 25–34 (in Russ.). DOI: 10.17802/2306-1278-2024-13-4-25-34
  17. Cochet H., Iriart X., Allain-Nicolaï A. et al. Focal scar and diffuse myocardial fibrosis are independent imaging markers in repaired tetralogy of Fallot. Eur. Heart J. Cardiovasc. Imaging. 2019; 20 (9): 990–1003. DOI: 10.1093/ehjci/jez068
  18. Ishikita A., Friedberg M.K., Wald R.M. Right ventricular fibrosis after tetralogy of fallot repair: can pulmonary valve replacement make a difference? JACC Basic. Transl. Sci. 2023; 8: 316–318. DOI: 10.1016/j.jacbts.2022.11.002
  19. Yamamura K., Yuen D., Hickey E.J. et al. Right ventricular fibrosis is associated with cardiac remodelling after pulmonary valve replacement. Heart. 2019; 105: 855–863. DOI: 10.1136/heartjnl-2018-313961

About Authors

  • Anton A. Lyapin, Cand. Med. Sci., Cardiovascular Surgeon; ORCID
  • Roman S. Tarasov, Dr. Med. Sci., Associate Professor, Head of Laboratory; ORCID
  • Artem A. Ivkin, Cand. Med. Sci., Head of Laboratory; ORCID

Chief Editor

Elena Z. Golukhova, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, Director of Bakoulev National Medical Research Center for Cardiovascular Surgery


Sort by